Volume 19, Issue 3

The treatment of children with Inflammatory Bowel Disease (IBD) presents unique challenges, largely due to the complex nature of the disease, the limitations of existing therapies in children and the common off-label use of "newer" agents. Paediatric IBD requires careful management to control inflammation, promote growth and maintain a good quality of life. The treatment armamentarium for IBD in adults has expanded rapidly in the past several years, with the approval of new biologic and small-molecule agents for moderate-to-severe Ulcerative Colitis (UC) and Crohn’s Disease (CD) [1–3].

Harry Sokol is a prominent gastroenterologist at Saint Antoine Hospital and Sorbonne Université and the President of the French Group of Faecal Microbiota Transplantation. In this edition of the ECCO Interview Corner, Professor Sokol shares his journey into gastroenterology, his pioneering work on Inflammatory Bowel Disease (IBD) and the gut microbiome and his vision for the future research.

Subcutaneous Infliximab (CT-P13) as Maintenance Therapy for Inflammatory Bowel Disease: 2 Randomized Phase 3 Trials Hanauer SB, Sands BE, Schreiber S, et al. Gastroenterology 2024.

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly-diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial Noor NM, Lee JC, Bond S, et al. Lancet Gastroenterol Hepatol 2024;9:415-427.

Continuous monitoring of CRP, IL-6, and calprotectin in Inflammatory Bowel Disease using a perspiration-based wearable device Shahub S, Kumar RM, Lin KC, et al. Inflamm Bowel Dis 2024 Mar 23; doi: 10.1093/ibd/izae054. Online ahead of print.

Dear Y-ECCO Friends, As we move into the final quarter of the year, this is the perfect time to reflect on our collective achievements and to set our sights on the exciting events that lie ahead.